« Previous
Next »
Titles
- CBO's model of drug price negotiations under the Elijah E. Cummings Lower Drug Costs Now Act1
- CBO's simulation model of new drug development1
- CMC postapproval manufacturing changes for specified biological products to be documented in annual reports2
- CMS could improve the data it uses to monitor antipsychotic drugs in nursing homes1
- CMS should pursue strategies to increase the number of at-risk beneficiaries acquiring naloxone through Medicaid1
- CMS use of data on nursing home staffing: progress and opportunities to do more1
- CMS’s encounter data lack essential information that Medicare Advantage organizations have the ability to collect1
- COVID-19 & veterans’ mental health fact sheet1
- COVID-19 and affordability of coverage and care for Medicare beneficiaries1
- COVID-19 and nursing home residents1
- COVID-19 container closure system and component changes: glass vials and stoppers1
- COVID-19 contracting: Indian Health Service used flexibilities to meet increased medical supply needs : report to congressional addressees1
- COVID-19 hospitalizations in Pennsylvania: March to June 20201
- COVID-19 illness personally affected nearly 97 million U.S. adults1
- COVID-19 in California's nursing homes: factors associated with cases and deaths1
- COVID-19 in nursing homes: HHS has taken steps in response to pandemic, but several GAO recommendations have not been implemented : testimony before the Committee on Finance, U.S. Senate1
- COVID-19 in nursing homes: most homes had multiple outbreaks and weeks of sustained transmission from May 2020 through January 2021 : report to Congressional addressees1
- COVID-19 intensifies nursing home workforce challenges1
- COVID-19 pandemic coincided with elevated and increasing anxiety and depression symptoms1
- COVID-19 pandemic: VA provides health care assistance to civilians as part of the federal response : report to Congressional addressees1